KLF2 and COVID-19: It has been well established that genetic and pharmacological activation of KLF2 reduces monocyte adhesion to activated endothelium.19,20 We thus investigated the role of KLF2 overexpression and atorvastatin on COVID-19-patient-serum-induced monocyte adhesion.